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Abstract
Acute flaccid myelitis is characterized by the combination of acute flaccid paralysis and a spinal cord lesion largely restricted to
the gray matter on magnetic resonance imaging. The term acute flaccid myelitis was introduced in 2014 after the upsurge of
pediatric cases in the USA with enterovirus D68 infection. Since then, an increasing number of cases have been reported
worldwide. Whereas the terminology is new, the clinical syndrome has been recognized in the past in association with several
other neurotropic viruses such as poliovirus.
Conclusion: This review presents the current knowledge on acute flaccid myelitis with respect to the clinical presentation and
its differential diagnosis with Guillain-Barré syndrome and acute transverse myelitis. We also discuss the association with
enterovirus D68 and the presumed pathophysiological mechanism of this infection causing anterior horn cell damage. Sharing
clinical knowledge and insights from basic research is needed to make progress in diagnosis, treatment, and prevention of this
new polio-like disease.
What is Known:
• Acute flaccid myelitis (AFM) is a polio-like condition characterized by rapid progressive asymmetric weakness, together with specific findings on MRI
• AFM has been related to different viral agents, but recent outbreaks are predominantly associated with enterovirus D68.
What is New:
• Improving knowledge on AFM must increase early recognition and adequate diagnostic procedures by clinicians.
• The increasing incidence of AFM urges cooperation between pediatricians, neurologists, and microbiologists for the development of treatment and
preventive options.
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Abbreviations
ADEM Acute disseminated encephalomyelitis
AFM Acute flaccid myelitis
AFP Acute flaccid paralysis
ATM Acute transverse myelitis
CDC Center for Disease Control and Prevention
CMAP Compound muscle action potential
CSF Cerebrospinal fluid
EMG Electromyography
EV-A71 Enterovirus A71
EV-D68 Enterovirus D68
GBS Guillain-Barré syndrome
IVIG Intravenous immunoglobulin
MRI Magnetic resonance imaging
WNV West Nile virus
Introduction
Acute flaccid myelitis (AFM) is a syndrome characterized by
acute flaccid paralysis (AFP) and gray matter spinal cord le-
sions on magnetic resonance imaging (MRI). After the intro-
duction of the term AFM in 2014, more than 500 patients,
predominantly children, have been recognized both in- and
outside Europe [5, 27, 32, 48].
The Center for Disease Control and Prevention (CDC) pro-
posed a case definition in which a definite AFM case is de-
scribed as acute-onset flaccid weakness, combined with a spi-
nal cord lesion on MRI, largely restricted to the gray matter
and spanning one or more spinal segments. Acute flaccid
weakness combined with cerebrospinal fluid (CSF)
pleocytosis without lesions on MRI is defined as a probable
case [4].
A prodromal illness, asymmetric limb weakness, and spe-
cific findings in electromyography and nerve conduction stud-
ies may further aid in distinguishing AFM from other causes
of AFP such as Guillain-Barré syndrome (GBS) and acute
transverse myelitis (ATM) [10].
Accumulating evidence supports an association between
enterovirus D68 (EV-D68) and AFM [9, 34]. Other viruses
that have been associated with outbreaks of acute flaccid
weakness and myelitis include enterovirus A71 (EV-A71),
West Nile virus (WNV), Japanese encephalitis virus, and the
wild-type poliovirus [12, 22, 43, 45].
In this review, we describe the clinical syndrome of AFM,
its differential diagnosis, and its association with different vi-
ruses, with the emphasis on EV-D68.
Methods
For this review, we performed a literature search in PubMed
on “flaccid myelitis” and “Enterovirus D68” from 2000 until
February 2019. A total of 995 titles of articles in English were
screened and selected based on relevance for epidemiology,
clinical characteristics, pathophysiology, treatment, preven-
tion, and prognosis of AFM. Only cohorts containing at least
five children were selected (Table 1).
Epidemiology
Before the term AFMwas introduced, outbreaks of acute flac-
cid weakness and myelitis, matching the case definition for
AFM, were reported in association with EV-A71, predomi-
nantly in Eastern Asia and Australia, and with WNV, causing
several outbreaks in the USA in the beginning of this century
[12, 22]. Poliomyelitis also matches the case definition of
AFM and can be seen as the first known cause of AFM.
However, MRI was and is often not available in countries
where poliomyelitis still occurs, making the definite diagnosis
of AFM difficult.
In 2012, the first probable cases were reported in California
(USA) [10]. Since 2014, the CDC has reported over 500 cases
of AFM in the USAwith 2-year intervals and several cohorts
of patients with AFM have been reported worldwide (Table 1)
[5, 10, 11, 23, 24, 31, 39, 40, 42, 48]. A recent study reported
an incidence of 1.46 per 100,000 person years, although reli-
able data is lacking, as AFM is notifiable in only few countries
and the clinical picture is often not recognized [25].
In different cohorts of AFM patients, EV-D68 was detected
in 20–40% of cases, primarily from respiratory specimens
(Table 1). The variation in detection percentages might be
explained by differences in timing and performance of diag-
nostic procedures and by selection criteria for patients [25].
Most reported patients with AFM were children under the age
of 10 with a slight male preponderance. A majority were pre-
viously healthy, but asthma was seen in 12–32% of children
[25, 33, 48].
Both EV-A71 and West Nile virus are still circulating and
have also been detected in recent cohorts of AFM patients [2,
3, 31]. Outbreaks of poliomyelitis are currently rare, due to a
global poliovirus surveillance and vaccination program [8].
Clinical features
The clinical characteristics of non-polio AFM cohorts de-
scribed in literature since 2012 are summarized in Table 1.
Muscle weakness typically develops over the course of sever-
al hours to days, often with a marked asymmetry. Weakness is
proximally usually more severe and may be more pronounced
in the upper limbs, with a spectrum of severity varying be-
tween slight paresis of a single limb to tetraplegia. Tendon
reflexes are typically diminished or absent in the affected
limbs. In most patients, there is a prior prodromal illness, often
involving the upper respiratory tract, with a median of 5 days
before onset of weakness [5, 10, 27, 33].
1306 Eur J Pediatr (2019) 178:1305–1315
Ta
bl
e
1
Su
m
m
ar
y
of
co
ho
rt
s
of
ch
ild
re
n
of
A
FM
de
sc
ri
be
d
af
te
r
20
12
,s
ho
w
in
g
pa
tie
nt
ch
ar
ac
te
ri
st
ic
s,
cl
in
ic
al
fi
nd
in
gs
,a
nd
fi
nd
in
gs
on
fu
rt
he
r
in
ve
st
ig
at
io
ns
A
ut
ho
r
In
cl
us
io
n
pe
ri
od
C
ou
nt
ry
/r
eg
io
n
N
o
pt
s
E
V
-D
68
po
s
G
en
de
r
(%
m
al
e)
A
ge
(m
ea
n
or
m
ed
ia
n
w
ith
ra
ng
e)
Pr
od
ro
m
e
(%
)
L
im
b
w
ea
kn
es
s
(%
)
A
sy
m
m
et
ry
(%
)
Se
ns
or
y
in
vo
lv
em
en
t(
%
)
1
A
nd
er
se
n
20
01
–2
01
4
A
us
tr
al
ia
8
0%
(1
3%
E
V
-A
71
)
25
M
ed
5
10
0
10
0
10
0
0
2
M
es
sa
ca
r
20
12
–2
01
5
U
SA
15
9a
20
–4
5%
56
–9
1
M
ed
7.
1
(0
.4
–7
3)
64
–1
00
83
–1
00
47
–7
0
21
–4
4
3
E
lr
ic
k
20
12
–2
01
6
U
SA
34
13
%
65
M
ed
5
(<
1–
15
)
10
0
10
0
97
0
4
Y
ea
20
14
C
an
ad
a
25
28
%
64
M
ed
7.
8
(0
.8
-1
5.
0)
88
10
0
N
S
12
5
G
or
do
n-
L
ip
ki
n
20
14
–2
01
7
U
SA
16
23
%
69
M
ed
4
(3
–6
)
10
0
10
0
N
S
6
6
C
ho
ng
20
15
Ja
pa
n
59
15
%
59
M
ed
4.
4
(2
.6
–7
7)
97
10
0
68
20
7
K
no
es
te
r
20
15
–2
01
6
E
ur
op
e
29
10
0%
b
52
M
ed
4
(1
.6
–5
5)
92
10
0
N
S
(u
su
al
)
7
8
B
on
w
itt
20
16
U
SA
10
20
%
(1
0%
E
V
-A
71
)
70
M
ed
6
(3
–1
4)
80
10
0
N
S
N
S
9
Iv
er
so
n
20
16
U
SA
5
60
%
20
M
ea
n
7.
7
(3
.5
–1
2)
10
0
10
0
N
S
N
S
10
H
üb
ne
r
20
16
G
er
m
an
y
16
(7
)c
6%
50
M
ea
n
4.
6
(1
.7
-1
4.
3)
10
0
10
0
86
N
S
11
R
ug
gi
er
i
20
16
A
rg
en
tin
a
11
36
%
54
M
ea
n
3.
2
(0
.3
–6
)
10
0
10
0
81
0
12
Sa
rm
as
t
20
17
In
di
a
9
0%
56
M
ed
5.
5
(2
–7
)
10
0
10
0
10
0
0
13
M
cK
ay
20
18
U
SA
80
37
%
(2
9%
E
V
-A
71
)
59
M
ed
4
(0
.7
–3
2)
99
10
0
N
S
N
S
14
R
am
sa
y
20
18
U
K
40
(1
6)
d
36
%
53
55
%
un
de
r
5
yo
55
98
N
S
N
S
H
yp
or
ef
le
xi
a
(%
)
C
ra
ni
al
ne
rv
e
dy
sf
un
ct
io
n
(%
)
V
en
til
at
or
y
su
pp
or
t
(%
)
B
ow
el
/b
la
dd
er
dy
sf
un
ct
io
n
(%
)
C
SF
pl
eo
cy
to
si
s
(%
)
Pr
ot
ei
n
ra
is
ed
in
C
SF
(%
)
M
R
I
sp
in
e:
T
2
hy
pe
ri
nt
en
si
ty
(%
)
N
er
ve
ro
ot
en
ha
nc
em
en
t
(%
)
B
ra
in
st
em
le
si
on
s
1
N
S
25
N
S
0
85
71
10
0
38
25
2
80
–8
1
18
–8
3
9–
34
18
–5
1
64
–9
1
45
–5
8
90
–1
00
20
–4
0
35
–7
5
3
67
>
24
24
6
97
45
10
0
38
62
4
88
>
20
28
36
72
28
10
0
72
32
5
63
50
31
N
S
10
0
N
S
(M
ed
6.
3
g/
L
)
10
0
13
42
6
90
17
8
27
85
46
10
0
51
42
7
87
60
66
7
91
N
S
(M
ed
3.
8
g/
L
)
92
16
68
8
N
S
30
10
50
78
N
S
(M
ed
5.
8
g/
L
)
10
0
0
30
9
N
S
80
N
S
N
S
10
0
N
S
80
N
S
N
S
10
N
S
N
S
14
N
S
43
N
S
86
N
S
N
S
11
10
0
45
36
0
63
18
10
0
N
S
45
12
10
0
11
N
S
0
89
22
10
0
N
S
11
13
N
S
N
S
N
S
N
S
83
N
S
(M
ed
4.
7
g/
L
)
10
0
N
S
N
S
14
N
S
N
S
55
N
S
18
N
S
43
N
S
N
S
N
o
pt
s,
nu
m
be
r
of
pa
tie
nt
s;
E
V-
D
88
,e
nt
er
ov
ir
us
D
68
;E
V-
A
71
,e
nt
er
ov
ir
us
A
71
;m
ed
,m
ed
ia
n;
C
SF
,c
er
eb
ro
sp
in
al
fl
ui
d;
M
R
I,
m
ag
ne
tic
re
so
na
nc
e
im
ag
in
g;
U
SA
,U
ni
te
d
St
at
es
of
A
m
er
ic
a;
U
K
,U
ni
te
d
K
in
gd
om
;N
S,
no
ts
pe
ci
fi
ed
;y
o,
ye
ar
ol
d
a
C
om
bi
na
tio
n
of
fo
ur
U
S
co
ho
rt
s
w
ith
a
pa
rt
ia
lo
ve
rl
ap
in
th
es
e
co
ho
rt
s
b
E
V
-D
68
ha
d
to
be
id
en
tif
ie
d
fo
r
in
cl
us
io
n
c
16
re
gi
st
er
ed
ca
se
s,
7
of
w
hi
ch
w
er
e
fu
rt
he
r
de
sc
ri
be
d
d
40
ca
se
s
of
A
cu
te
Fl
ac
ci
d
Pa
ra
ly
si
s,
of
w
hi
ch
16
fu
lf
ill
ed
th
e
cr
ite
ri
a
fo
r
pr
ob
ab
le
or
de
fi
ni
te
A
FM
Eur J Pediatr (2019) 178:1305–1315 1307
Weakness can be limited to the extremities, but the dia-
phragm and bulbar muscles may also be affected, making
ventilatory support necessary in the acute phase in about
30% of cases [10, 13, 33, 48]. Cranial nerve deficits are com-
mon and may be the only finding. The facial nerve is most
often affected, followed by the abducens and oculomotor
nerves [33].
Associated features include severe limb pain and autonom-
ic disturbances such as bladder dysfunction. Sensory symp-
toms, primarily paresthesia, are reported in up to 20% of cases
[5, 10, 27, 33].
The clinical features of cohorts of AFM, described before
2012, associated with EV-A71, WNV, and poliovirus were
highly similar, although poliovirus-related AFM more often
affected lower limbs, with bulbar muscles usually being
spared [43]. EV-A71 has also been associated with
rhombencephalitis, sometimes with severe cardiorespiratory
symptoms [12, 22, 43].
Differential diagnosis
AFM is included in the broad differential diagnosis of AFP.
AFP is defined as a syndrome of focal weakness of peripheral
origin in any part of the body with an acute onset [30].
It is important to be able to recognize AFM early in its
course so that adequate diagnostic procedures can be per-
formed and respiratory failure in the initial phase can be an-
ticipated. Both clinical clues and findings on further investi-
gations may help differentiate AFM from other causes of AFP.
In cases of AFM in which only one arm is affected, the
initial thought may be that of synovitis or arm injury. Clinical
clues that may help in distinguishing these from AFMmay be
the presence of a prodromal illness, the hypo- or areflexia, and
the often-associated neck weakness in AFM.
When more than one limb is affected, the differential diag-
nosis includes other causes of acute myelopathy, such as acute
transverse myelitis (ATM), acute disseminated encephalomy-
elitis (ADEM), acute cord compression, and ischemic mye-
lopathy. Furthermore, Guillain-Barré syndrome (GBS) may
be suspected because of the sudden onset of flaccid weakness
after a prodromal illness.
While the asymmetric weakness, the absence of encepha-
lopathy, the paucity of sensory symptoms, and the presence of
cranial nerve deficits in AFM may help in distinguishing it
from other causes of AFP, further investigations are required
to make the right diagnosis (Table 2; Figs. 1, 2, 3, 4) [1, 10, 20,
33, 47].
Investigations
Diagnostic tests recommended in children with suspected
AFM should be directed at the identification of different mi-
croorganisms and the exclusion of other causes (Table 3) [15].
Initial investigations must be performed on blood, stool, re-
spiratory material, and CSF, followed byMRI of the brain and
spinal cord and in some cases electromyography (EMG).
Blood
General laboratory investigation of blood samples of AFM
patients may show a slight leukocytosis, sometimes with
raised inflammatory parameters, which is usually not helpful
in the differentiation of AFM from other disorders causing
AFP [20, 33].
Cerebrospinal fluid
CSF examination in AFM patients in the described cohorts
since 2012 reveals a mild to moderate pleocytosis in most
cases (Table 1). Protein levels are initially minimally raised
in about half of AFM cases but can be completely normal.
After several days, the leukocyte number tends to decrease,
while protein levels rise [5, 14, 27, 33]. Oligoclonal bands in
the CSF can be identified in immune-mediated conditions
such as ATM, but are usually not found in AFM [1].
Interestingly, viral agents, such as EV-D68, EV-A71, and
poliovirus, are only detected in the CSF in a small minority of
patients with AFM [5, 22, 27, 40, 43].
Virology diagnostic testing
The viral RNA of EV-D68 is detected mostly in respiratory
samples, followed to a much lesser extent by feces and can
only rarely be found in blood or CSF. This in contrast to EV-
A71, which is more frequently detected in blood, and polio-
virus, which is routinely identified in stool samples [15, 43].
Obtaining an adequate respiratory sample is therefore in-
dispensable for detection of EV-D68. Considering the fact that
the prodromal, mostly respiratory illness is usually a few days
into its natural course when a patient presents with weakness,
the best chances of detecting EV-D68 is soon after onset of
complaints. Several PCR tests have been described, which test
either directly for EV-D68 or for enteroviruses in general [15,
38].
Magnetic resonance imaging
MRI of the brain and spinal cord is important in making the
diagnosis of AFM and in distinguishing it from other causes of
AFP (Table 2 and Figs. 1, 2, 3, 4) [13]. CT usually shows no
abnormalities [28].
In AFM, the classical MRI feature is a longitudinally ex-
tensive slight T2-hyperintense signal in the central cord, af-
fecting the central gray matter, often most pronounced in the
cervical regions (Fig. 1b, c). Initially, there is usually more
diffuse spinal cord edema, evolving over several days to T2-
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hyperintensity that is restricted to the anterior horn.
Enhancement of the caudal roots and sometimes of the cranial
nerves can be seen (Fig. 1d) [28].
MRI of the brain commonly reveals an area of slight
hyperintensity typically located in the dorsal pons in the re-
gion of the nuclei of the abducens and facial nerve. The
corticospinal tracts, located ventrally, are not affected
(Fig. 1a), while the caudate nucleus may be involved [28].
These findings may help in securing the diagnosis, but the
correlation between symptoms and radiologic findings is usu-
ally poor, making MRI unsuitable as a prognostic tool for
AFM [37].
Imaging findings in earlier outbreaks of AFM, associated
with WNV and poliovirus, were highly similar, while in EV-
A71–associated neurological disease, these appear to be more
variable and more extensive brain abnormalities may occur [6,
12, 22].
Neurophysiological studies
While EMG findings in recent outbreaks of AFM can be nor-
mal on the first day, after several days, a pattern compatible
with anterior horn disease is seen. This encompasses de-
creased compound muscle action potentials (CMAP) with
normal conduction velocities. Sensory testing is usually
completely normal [21].
After some weeks, denervation potentials can be seen, with
severe ongoing denervation being a possible predictor for the
gravity of residual damage. The persistence of F-waves may
indicate a better prognosis [5, 21, 33].
Virology
Enteroviruses, such as EV-D68, EV-A71, and poliovirus, are
small RNA viruses belonging to the picornavirus family. EV-
D68 was first identified in 1962 after isolation from children
with severe respiratory disease [44]. Since 2012, an increasing
incidence has been recognized, with infections mostly occur-
ring in autumn and late summer. EV-D68 appears to occur in a
cyclic pattern with a 2-year interval [27, 34].
EV-D68 infection may be asymptomatic or cause respira-
tory disease. In hospitalized children, an asthma-like respira-
tory disease is most commonly seen [39]. The percentage of
infected patients afflicted with paralytic disease is not yet
known, but is estimated to be less than 1%, similar to polio-
myelitis [29, 43].
Pathophysiology
A causal relationship between EV-D68 and AFM is supported
by epidemiological and biological evidence, as was evaluated
by different groups applying the Bradford Hill criteria [9, 34].
The biological evidence mainly came from mouse models,
in which mice infected with contemporary circulating strains
of EV-D68 develop flaccid paralysis mimicking AFM.
Interestingly, neonatal or young mice are used, because older
mice are not susceptible to disease [17, 36]. Pathologic exam-
ination of infected mice revealed the presence of the virus in
the anterior horn with associated cell loss [17, 36]. EV-D68
probably reaches the anterior horn by retrograde axonal trans-
port, as is supported by bothmouse studies and in vitro studies
in human motor neurons [17, 19, 36].
One study found myositis without spinal cord infection
after intranasal injection of the virus in mice [36].
Although the results from mouse studies cannot simply be
extrapolated to humans, these results are suggestive of a dam-
aging effect of the virus in anterior horn cells, possibly com-
bined with a direct damaging effect on muscles through viral
myositis.
Important questions remain why only some EV-D68 infect-
ed patients develop AFM and how the variability in severity of
AFM in affected patients is explained.
Treatment
There are currently no effective treatment options for AFM.
Most patients are treated with intravenous immunoglobulin
(IVIG), steroids, or plasmapheresis, or a combination, but no
significant clinical effect of any of these interventions has
been shown so far. Because of its effectiveness in the mouse
model of EV-D68–associated AFM and its possible efficacy
in treatment of EV-A71–associated encephalomyelitis, treat-
ment with IVIG has been recommended [18, 33, 46, 48].
The anti-inflammatory effects of steroids may be beneficial
in AFM cases with spinal cord edema or white matter involve-
ment, but steroids are unlikely to be effective in limiting the
anterior horn damage that is probably caused by a direct dam-
aging effect of the virus. Furthermore, treatment with steroids
in a mouse model of AFM associated with EV-D68 led to an
increased viral load and a deterioration of motor symptoms
[17, 36].
Fluoxetine, an antidepressant, is effective in inhibiting EV-
D68 replication in vitro. However, treatment with fluoxetine
in the mouse model of EV-D68–associated AFM did not result
in reduction of the viral load or improvement of motor func-
tion. Also, no significant effect has been shown in patients
with AFM, treated with fluoxetine [18, 35].
While scientific proof is still lacking, we recommend IVIG
in the acute phase, combined with maximal supportive care
with optimal pain control, feeding, ventilatory support, and
intensive rehabilitation. Surgical procedures such as nerve
and muscle transfers have been performed and cases have
been described in which improvement of limb function has
been achieved. Because over time degeneration of the receiv-
ing motor nerves and muscle fibers will occur, evaluation for
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surgical intervention should be considered early in the disease
course [41].
Prevention/vaccination
In the mouse model of EV-D68–associated AFM, passive im-
munization with pooled immune sera, if administered before
injection of the virus, was effective in decreasing the rate of
paralysis [18].
Arguments for vaccination as a treatment strategy arise
from the development of effective vaccines against EV-A71
infections in China and the effective eradication of poliomy-
elitis in most of the world after introduction of vaccination [8,
49]. Recently, an experimental vaccine based on virus-like
particles targeting EV-D68 has been developed. This vaccine
has been proven effective in a mouse model in the prevention
of AFM [7].
Prognosis
Only 5–39% of patients with AFM recover partially to
completely (supplementary table 1). Most patients retain
Fig. 2 MRI of the spinal cord in a
3-year-old boy with Guillain-
Barré syndrome. a Sagittal
contrast-enhanced T1 showing
typical enhancing anterior caudal
roots. b Subtraction of Awith
more clear depiction of enhancing
caudal root. c Transverse T1
showing more clear enhancement
of anterior motor roots
Fig. 1 MRI of the neuraxis in a 3-year-old boy with EV-D68–associated
AFM. a Brain: transverse T2-weighted image showing an area of slight
hyperintensity in the dorsal pons (arrow). b and c Spinal cord: sagittal T2-
weighted images showing longitudinal slight hyperintensity largely
restricted to the central cord, where the gray matter is situated (arrow).
d Spinal cord: contrast enhancement of the ventral caudal roots on a
sagittal T1-weigthed image (arrow) (republished with permission from
[16])
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Fig. 4 MRI of a 13-year-old boy
with a provisional diagnosis of
acute demyelinating
encephalomyelitis. a Sagittal
short tau inversion recovery
(STIR) with edematous
cervicothoracic spinal cord from
the level of C4. b Sagittal T1 of
the spinal cord showing diffuse
areas of slight enhancement. c
Enhancement of mainly dorsal
roots in a sagittal T1 of the lumbar
spine. d and e Transverse T2 at
the level of the pons (d) and
thalamus (e) showing asymmetric
hyperintense areas.
Fig. 3 MRI of the spinal cord in a
15-year-old boy with acute
transverse myelitis, eventually
diagnosed with relapsing
remitting multiple sclerosis. a
Sagittal T2 showing focal
swelling of the spinal cord at level
Th11–12. b Sagittal T1 showing
contrast enhancement of the
lesion
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significant residual motor deficits, and prolonged need for
ventilatory support is not uncommon. On follow-up, residual
proximal weakness tends to be more severe than distal weak-
ness, with severe atrophy occurring over time [5, 13, 23, 26,
29, 48]. Cranial nerve deficits usually recover well over time.
Death is uncommon but has been reported in immunocompro-
mised patients, usually because of respiratory complications
[27, 33]. While not much is known about prognostic factors,
more severe disability and weakness at nadir and the persis-
tence of denervation seem to be associated with worse out-
come. One study found a correlation between negative tests
for EV-D68 at onset and better outcome, which made the
authors speculate that viral clearance and host responses play
a role in the severity of weakness in AFM [5]. Alternatively,
these EV-D68–negative cases may be due to different etiolo-
gies associated with more favorable outcomes than cases con-
firmed to be associated with EV-D68.
Conclusion and future perspectives
AFM is a newly introduced term comprising AFP combined
with longitudinally extensive lesions of the spinal cord on
MRI. This syndrome resembles poliomyelitis and has been
associated with different viruses, in particular EV-D68.
EV-D68 infection is usually asymptomatic or mildly symp-
tomatic with respiratory illness, but it can be associated with
anterior horn disease causing severe weakness, with only min-
imal improvement over time in most cases.
A major challenge lies in the propagation of correct diag-
nostic procedures, including viral testing on respiratory mate-
rial in suspected AFM cases. Future research may identify risk
factors for AFM in EV-D68–infected patients and will eluci-
date how these factors can be influenced.
We believe that worldwide collaboration between neurolo-
gists, radiologists, pediatricians, and microbiologists is
necessary to make progress in preventing and treating this
devastating childhood disease. Furthermore, we postulate that
making AFM a notifiable disease in more countries can in-
crease awareness among clinicians and governments.
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